Cartesian Therapeutics, Inc. (RNAC)
(Delayed Data from NSDQ)
$13.37 USD
+0.50 (3.89%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $13.22 -0.15 (-1.12%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Cartesian Therapeutics, Inc. [RNAC]
Reports for Purchase
Showing records 1 - 9 ( 9 total )
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MG Data Tees Up Phase 3; Deep Response Upon Redosing; Adjusting PT Down to $49
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Descartes-08 Can Shine Where Rivals Stumble; MG Data Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
RMAT Designation Earned for Descartes-08 in Myasthenia Gravis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Phase 2b Data Release Imminent; 1Q24 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data Mid-2024 a Crucial Inflection Point; Reverse Split; Adjusting PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Astellas Terminates Xork Collaboration; No Impact to Value; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Descartes-08 Phase 2b Data in Mid-2024; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Manufacturing Facility Should Drive Production Scale; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Cartesian Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A New Formula for CAR-T in Autoimmunity; Assuming at Buy and $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
|